Literature DB >> 20484895

Uremia aggravates left ventricular remodeling after myocardial infarction.

Ralf Dikow1, Ulrike Schmidt, Lars P Kihm, Matthias Schaier, Vedat Schwenger, Marie-Luise Gross, Hugo A Katus, Martin Zeier, Stefan E Hardt.   

Abstract

BACKGROUND: Renal failure is a well-established cardiovascular risk factor. We hypothesized that uremia negatively affects post-myocardial infarction (MI) remodeling and left ventricular (LV) function and examined the pathohistological correlations.
METHODS: Subtotally nephrectomized rats (SNX) and controls with MI only (MIC) were examined 1, 4 and 8 weeks after MI. MI size, ejection fraction (EF), cardiac fibrosis, vascular density and cardiomyocyte density were studied.
RESULTS: The extension of MI was 0.08 +/- 0.02 in SNX versus 0.06 +/- 0.02 in MIC rats (p < 0.031). Prior to MI, EF was comparable in SNX and MIC (74 +/- 3 vs. 72 +/- 2%, n.s.). Despite a relatively small infarct size EF in SNX decreased to 58 +/- 4% 1 week after infarction and progressively worsened to 51 +/- 4% after 8 weeks. In MIC animals EF only slightly decreased 1 week after MI (70 +/- 3%) and remained unchanged at follow-up. In SNX animals LV end-diastolic diameter continuously increased following MI throughout the study period indicating accelerated remodeling. Furthermore, accelerated myocardial fibrosis was already notable 1 week after MI in SNX animals and the volume density of capillaries and cardiomyocytes was significantly lower in SNX rats.
CONCLUSION: MI in experimental uremia is associated with progressive impairment of LV function, LV dilatation and accelerated myocardial fibrosis. Copyright 2010 S. Karger AG, Basel.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20484895     DOI: 10.1159/000313846

Source DB:  PubMed          Journal:  Am J Nephrol        ISSN: 0250-8095            Impact factor:   3.754


  7 in total

1.  Mitochondrial dysfunction in uremic cardiomyopathy.

Authors:  David Taylor; Sunil Bhandari; Anne-Marie L Seymour
Journal:  Am J Physiol Renal Physiol       Date:  2015-01-13

Review 2.  Is left ventricular hypertrophy a modifiable risk factor in end-stage renal disease.

Authors:  David Charytan
Journal:  Curr Opin Nephrol Hypertens       Date:  2014-11       Impact factor: 2.894

3.  Increased cardiovascular risk in rats with primary renal dysfunction; mediating role for vascular endothelial function.

Authors:  M K Szymanski; J H Buikema; D J van Veldhuisen; J Koster; J van der Velden; N Hamdani; J L Hillege; R G Schoemaker
Journal:  Basic Res Cardiol       Date:  2012-01-19       Impact factor: 17.165

Review 4.  Animal models of cardiorenal syndrome: a review.

Authors:  Mariusz K Szymanski; Rudolf A de Boer; Gerjan J Navis; Wiek H van Gilst; Hans L Hillege
Journal:  Heart Fail Rev       Date:  2012-05       Impact factor: 4.214

5.  Effect of Gamma-Oryzanol as Therapeutic Agent to Prevent Cardiorenal Metabolic Syndrome in Animals Submitted to High Sugar-Fat Diet.

Authors:  Fabiane Valentini Francisqueti; Igor Otávio Minatel; Artur Junio Togneri Ferron; Silméia Garcia Zanati Bazan; Vanessa Dos Santos Silva; Jéssica Leite Garcia; Dijon Henrique Salomé de Campos; Ana Lúcia Ferreira; Fernando Moreto; Antonio Carlos Cicogna; Camila Renata Corrêa
Journal:  Nutrients       Date:  2017-11-29       Impact factor: 5.717

6.  Histamine receptor agonist alleviates severe cardiorenal damages by eliciting anti-inflammatory programming.

Authors:  Kazuyuki Noguchi; Junji Ishida; Jun-Dal Kim; Naoto Muromachi; Koichiro Kako; Hayase Mizukami; Weizhe Lu; Tomohiro Ishimaru; Shohei Kawasaki; Shuzo Kaneko; Joichi Usui; Hiroshi Ohtsu; Kunihiro Yamagata; Akiyoshi Fukamizu
Journal:  Proc Natl Acad Sci U S A       Date:  2020-01-28       Impact factor: 11.205

7.  Pathophysiological model of chronic heart failure complicated with renal failure caused by three-quarter nephrectomy and subcutaneous injection of isoprenaline.

Authors:  Ding-Feng Peng; Shao-Yong Tang; Yong-Jun Hu; Jiao Chen; Li Yang
Journal:  Exp Ther Med       Date:  2012-12-19       Impact factor: 2.447

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.